Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma

(2011) Camillo Porta et al.   EUROPEAN JOURNAL OF CANCER

Toxicities of Targeted Therapy and Their Management in Kidney Cancer

(2011) Giuseppe Di Lorenzo et al.   EUROPEAN UROLOGY

Future Directions in Renal Cell Carcinoma: 2011 and Beyond

(2011) Daniel C. Cho et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus

(2011) Jose Pablo Maroto et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-Associated Adverse Event Management in the Advanced Renal Cell Carcinoma Patient Treated with Targeted Therapies

(2011) A. Ravaud   ONCOLOGIST

Imaging of Pulmonary Viral Pneumonia

(2011) Tomás Franquet   RADIOLOGY

Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma

(2010) Dorothy A. White et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Introduction

(2010)   ANNALS OF ONCOLOGY

Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma

(2010) Jesus Rodriguez-Pascual et al.   ANTI-CANCER DRUGS

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Signaling pathways in renal cell carcinoma

(2010) Gowrishankar Banumathy et al.   CANCER BIOLOGY & THERAPY

Safety profile of new anticancer drugs

(2010) Laura Mansi et al.   Expert Opinion On Drug Safety

Everolimus-related organizing pneumonia: a report establishing causality

(2010) Justine Frija et al.   INVESTIGATIONAL NEW DRUGS

Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer

(2010) Toshihiko Doi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies

(2010) Bertrand Coiffier et al.   LEUKEMIA & LYMPHOMA

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

(2010) Darcy A. Krueger et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma

(2010) V. E. Kwitkowski et al.   ONCOLOGIST

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

(2009) J.-C. Soria et al.   ANNALS OF ONCOLOGY

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

(2009) Robert J. Amato et al.   CANCER

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)

(2009) Dorothy A. White et al.   Journal of Thoracic Oncology

Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma

(2009) Gary R. Hudes et al.   SEMINARS IN ONCOLOGY

Treatment Modalities for Leptomeningeal Metastases

(2009) William R. Shapiro et al.   SEMINARS IN ONCOLOGY

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

(2009) Kamalesh Sankhala et al.   Targeted Oncology

Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options

(2009) Jörg Schrader et al.   TRANSPLANT INTERNATIONAL

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

(2008) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors

(2008) Bobbak Vahid et al.   CHEST

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY

Cathepsin-k expression in pulmonary lymphangioleiomyomatosis

(2008) Marco Chilosi et al.   MODERN PATHOLOGY

Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

(2008) T. E. Hutson et al.   ONCOLOGIST

Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma

(2007) Naeem Bhojani et al.   EUROPEAN UROLOGY